B&L'S CHIRON VISION PURCHASE COULD INCLUDE FDA-APPROVED REFRACTIVE LASER
This article was originally published in The Gray Sheet
Bausch & Lomb's acquisition of Chiron Vision could put it in the U.S. refractive laser surgery market. Chiron Vision has a premarket approval application pending for a refractive excimer laser, and expects a decision from FDA by the end of the year. B&L announced a definitive agreement to buy Chiron Vision for $300 mil. cash on Oct. 20; the deal is expected to close in early 1998.
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.